Lapatinib benefits found for HER2-positive early-stage patients

[News]

Women with early-stage, HER2-positive breast cancer who are unable to use trastuzumab may benefit from adjuvant lapatinib treatment, suggest phase III trial findings published in Lancet Oncology.

More... (http://www.news-medical.net/news/20121217/Lapatinib-benefits-found-for-HER2-positive-early-stage-patients.aspx)